Ishita Drugs & Indus Intrinsic Value
Ishita Drugs & Indus (ISHITADR) median intrinsic value is ₹49.75 from 9 valuation models (range ₹24–₹113), vs current price ₹78.61 — -36.7% downside (Trading Above Calculated Value), margin of safety -58.0%. Browse Ishita Drugs & Indus financial data for revenue, profit, balance sheet and cash flow data.
ISHITADR Valuation Methods Summary — DCF, Graham Number & P/E
Ishita Drugs & Indus intrinsic value across 9 models vs current price ₹78.61 — upside/downside and value range per method. For current market price and key ratios, visit Ishita Drugs & Indus share price today.
| Method | Type | Intrinsic Value | Range | Upside/Downside | Details |
|---|---|---|---|---|---|
| P/E Based Valuation | earnings | ₹66.00 | ₹52.80 - ₹79.20 | -16.0% | EPS: ₹3.00, Sector P/E: 22x |
| Book Value Method | asset | ₹73.33 | ₹66.00 - ₹80.66 | -6.7% | Book Value/Share: ₹36.67, P/B: 2.0x |
| Revenue Multiple Method | revenue | ₹113.33 | ₹102.00 - ₹124.66 | +44.2% | Revenue/Share: ₹56.67, P/S: 2.0x |
| EBITDA Multiple Method | earnings | ₹33.33 | ₹30.00 - ₹36.66 | -57.6% | EBITDA: ₹1.00Cr, EV/EBITDA: 10x |
| Simple DCF (5Y) | dcf | ₹61.89 | ₹49.51 - ₹74.27 | -21.3% | CF Growth: 5.0%, Discount: 15% |
| PEG Ratio Method | growth | ₹23.58 | ₹21.22 - ₹25.94 | -70.0% | EPS Growth: 2.8%, Fair P/E: 2.2x |
| Growth Adjusted P/E | growth | ₹46.12 | ₹41.51 - ₹50.73 | -41.3% | Revenue Growth: 5.0%, Adj P/E: 15.4x |
| ROE Based Valuation | profitability | ₹39.30 | ₹35.37 - ₹43.23 | -50.0% | ROE: 9.1%, P/E Multiple: 10x |
| Graham Defensive Method | conservative | ₹49.75 | ₹44.77 - ₹54.73 | -36.7% | EPS: ₹3.00, BVPS: ₹36.67 |
ISHITADR Intrinsic Value vs Market Price — All Valuation Models
Ishita Drugs & Indus fair value range ₹24–₹113 vs current market price ₹78.61 across 9 valuation models. Also explore ISHITADR price trends to track price trends across different timeframes.
ISHITADR Intrinsic Value Analysis — Undervalued or Overvalued?
Ishita Drugs & Indus median intrinsic value ₹49.75, current price ₹78.61 — Trading Above Calculated Value by 36.7%, margin of safety -58.0%.
What is the intrinsic value of ISHITADR?
Based on our comprehensive analysis using 9 different valuation methods, the estimated intrinsic value of Ishita Drugs & Indus (ISHITADR) is ₹49.75 (median value). With the current market price of ₹78.61, this represents a -36.7% variance from our estimated fair value.
The valuation range spans from ₹23.58 to ₹113.33, indicating ₹23.58 - ₹113.33.
Is ISHITADR undervalued or overvalued?
Based on our multi-method analysis, Ishita Drugs & Indus (ISHITADR) appears to be trading above calculated value by approximately 36.7%.
ISHITADR Financial Health — Key Ratios vs Industry Benchmarks
Ishita Drugs & Indus financial ratios — ROE, debt-to-equity, profit margins and liquidity vs industry benchmarks and their impact on intrinsic value.
| Financial Metric | Current Value | Industry Benchmark | Assessment | Impact on Valuation |
|---|---|---|---|---|
| Return on Equity | 9.1% | Industry Standard: 15%+ | Below 10% | Measures shareholder return efficiency |
| Operating Margin | 6.0% | Industry Standard: 20%+ | Below 10% | Indicates operational efficiency level |
| Asset Turnover Ratio | 1.06x | Industry Standard: 1.0x+ | Above 1.0x | Measures asset utilization efficiency |
ISHITADR Cash Flow Quality — Operating & Free Cash Flow
Ishita Drugs & Indus operating cash flow, free cash flow, quality rating and sustainability score by period — key inputs to DCF intrinsic value calculation.
| Period | Operating Cash Flow | Free Cash Flow | Cash Flow Quality | Sustainability Score |
|---|---|---|---|---|
| March 2025 | ₹-4 Cr | ₹-5 Cr | Negative Cash Flow | 3/10 |
| March 2024 | ₹2 Cr | ₹2 Cr | Positive Free Cash Flow | 8/10 |
| March 2023 | ₹-3 Cr | ₹-3 Cr | Negative Cash Flow | 3/10 |
| March 2022 | ₹3 Cr | ₹3 Cr | Positive Free Cash Flow | 8/10 |
| March 2021 | ₹-1 Cr | ₹-1 Cr | Negative Cash Flow | 3/10 |